Welcome to our dedicated page for Merus N.V. Common Shares news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus N.V. Common Shares stock.
Merus N.V. (Nasdaq: MRUS) is a clinical-stage immuno-oncology company focused on creating innovative therapies to treat and potentially cure cancer. At the heart of Merus' approach is its proprietary Biclonics® and Triclonics® technology platforms, which generate full-length human bispecific and trispecific antibodies. These advanced therapeutics are designed to engage the immune system to kill tumor cells and inhibit tumor cell growth pathways simultaneously.
Core Business
Merus' core business revolves around the discovery and development of bispecific antibody therapeutics. Their flagship technology, Biclonics®, can attack tumors in multiple ways, making them highly effective against various cancer types. The company’s portfolio includes several promising candidates, such as MCLA-128, which targets HER2 and HER3 receptors in gastric and breast cancers; MCLA-117, targeting AML; MCLA-158 (petosemtamab), focused on head and neck squamous cell carcinoma; and MCLA-145, developed for solid tumors.
Latest Achievements and News
As of May 2024, Merus has received the FDA's Breakthrough Therapy Designation (BTD) for petosemtamab in treating patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has progressed after treatment with platinum-based chemotherapy and PD-1/PD-L1 antibodies. This significant milestone is based on the promising data from the ongoing phase 1/2 trial of petosemtamab as a monotherapy, showing substantial improvement in clinically significant endpoints. Furthermore, Merus has announced plans to initiate a phase 3 trial in mid-2024 to evaluate the combination of petosemtamab and pembrolizumab in previously untreated patients.
Additionally, Merus revealed the acceptance of abstracts for MCLA-145 and MCLA-129 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These presentations highlighted the clinical activity of MCLA-145 in advanced solid tumors and the efficacy of MCLA-129 in non-small cell lung cancer (NSCLC).
Financial Condition and Partnerships
Merus has a solid financial foundation, bolstered by strategic partnerships and collaborations. Notably, Merus collaborates with Betta Pharmaceuticals to develop MCLA-129 in China while retaining global rights outside China. The company’s financial strategy includes advancing its clinical development programs and supporting preclinical research and technology development through successful capital raises.
About Merus N.V.
Merus N.V. is dedicated to the development of multispecific antibody therapeutics, referred to as Multiclonics®. These therapeutics have been observed in preclinical and clinical studies to exhibit the same features as conventional human monoclonal antibodies, including long half-life and low immunogenicity. For more information, visit Merus’ official website, Twitter, and LinkedIn.
Merus N.V. (MRUS) reported Q3 2020 financial results, showing total revenue of $8.57 million, a slight increase from $8.15 million in Q3 2019. Collaboration revenue increased by $0.3 million, driven by higher Incyte reimbursements, while other revenues saw a decline. R&D expenses rose to $17.54 million due to increased costs related to their lead program, Zenocutuzumab (Zeno), which is in clinical trials for NRG1 fusion cancers. The company ended the quarter with $190.2 million in cash and expects this will fund operations into H2 2022.
myTomorrows and Merus are expanding their collaboration to enhance screening and recruitment for patients with neuregulin 1 (NRG1) fusion cancers. Under their 2019 agreement, myTomorrows has supported eligible patients in Merus’ Early Access Program for zenocutuzumab (Zeno). The new phase includes raising awareness of molecular screening for pancreatic cancer and increasing patient enrollment in Merus’ eNRGy clinical trial, aimed at assessing the safety and efficacy of Zeno in NRG1+ cancers.
Merus (Nasdaq: MRUS), a clinical-stage oncology company, announced that its President and CEO, Bill Lundberg, M.D., will present a company overview at the 2020 Wedbush PacGrow Healthcare Conference. The presentation is scheduled for August 12, 2020, at 10:20 a.m. ET.
A live webcast will be available on the company's website, along with an archived presentation for a limited time.
Merus specializes in developing innovative full-length multispecific antibodies, known as Biclonics® and Triclonics™.
Merus N.V. (MRUS) reported its Q2 2020 financial results, highlighting an extended cash runway into the second half of 2022. The company appointed Dr. Andrew Joe as Chief Medical Officer, enhancing its clinical development expertise. Collaboration revenue fell to $0.2 million, while total revenue decreased to $6.1 million. Research and development expenses increased by $2.9 million, driven by higher personnel and pre-clinical costs. The net loss rose to $17.9 million, and cash and cash equivalents decreased to $152.1 million, reflecting operational cash use.
Merus N.V. (Nasdaq: MRUS) has received Orphan Drug Designation from the FDA for Zenocutuzumab (Zeno), a bispecific antibody targeting pancreatic cancer. This designation highlights the unmet need for treatments in this area and offers potential benefits like grant funding and market exclusivity. Zeno has shown promise in early clinical trials for patients with NRG1 gene fusions, rare drivers of cancer growth. Merus is currently conducting a global Phase 1/2 clinical trial, the eNRGy trial, to assess Zeno's efficacy in NRG1+ cancers, including pancreatic and lung cancer.
Merus N.V. (Nasdaq: MRUS) has appointed Andrew Joe, M.D., as Chief Medical Officer, effective immediately. Dr. Joe has over 20 years of oncology drug development experience. He previously led immuno-oncology at Sanofi and contributed to significant approvals, including LIBTAYO and KEYTRUDA. At Merus, he will focus on advancing the clinical pipeline for multispecific antibodies, particularly Zenocutuzumab for NRG1 fusion cancers. This strategic appointment aims to enhance clinical execution and supports the company's personalized medicine approach.
Merus (Nasdaq: MRUS) collaborates with Caris Life Sciences to enhance patient identification for the Zenocutuzumab Phase 1/2 eNRGy trial focused on targeting NRG1 fusions in cancers such as pancreatic cancer. Caris will conduct whole exome and transcriptome sequencing to identify these fusions, potentially driving enrollment in the trial. The NRG1 fusion is a critical cancer growth factor, and Zeno is designed to inhibit its activity, offering promise for treating NRG1+ cancers. The collaboration aims to raise awareness and improve enrollment in the clinical trial.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg, M.D., will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 3:30 p.m. ET. A live webcast will be available on the company's website, with a replay accessible for a limited time post-event. Merus focuses on developing innovative full-length multispecific antibodies, known as Biclonics®, which demonstrate features similar to conventional human monoclonal antibodies, including a long half-life and low immunogenicity.
Merus N.V. (Nasdaq: MRUS) announces acceptance of six abstracts for the upcoming ASCO20 and EHA 2020 congresses. Key highlights include an independent epidemiology study reaffirming the clinical potential of zenocutuzumab (MCLA-128) in NRG1 fusion cancers and limited activity of MCLA-117 in AML trials. Zenocutuzumab has shown promise in NRG1+ pancreatic and lung cancers and will continue in clinical trials. MCLA-117's interim data suggest mild activity but insufficient for further enrollment. Both presentations will provide insights on T-cell engager development.
Merus N.V. (Nasdaq: MRUS) reported its Q1 2020 financial results, revealing a collaboration revenue decline to $6.3 million from $8.8 million year-over-year. The net loss increased to $16.5 million compared to $7.1 million in Q1 2019, reflecting higher operating expenses of $25.9 million, up from $18.5 million. Despite challenges from COVID-19, clinical trials for zenocutuzumab and other candidates remain on track, with an update expected by year-end. The company anticipates sufficient funds to support operations into 2022.
FAQ
What is the current stock price of Merus N.V. Common Shares (MRUS)?
What is the market cap of Merus N.V. Common Shares (MRUS)?
What is the core business of Merus N.V.?
What are some of Merus' key product candidates?
What significant recent achievement has Merus reported?
What are Biclonics®?
What is the status of MCLA-145 and MCLA-129?
What are Multiclonics®?
Who are Merus' key partners?
What are the financial strategies of Merus?
What is the purpose of the latest capital raise by Merus?
Where can I find more information about Merus N.V.?
